• Something wrong with this record ?

The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker

O. Mayer, J. Gelžinský, J. Seidlerová, M. Mateřánková, Š. Mareš, V. Svobodová, L. Trefil, R. Cífková, J. Filipovský

. 2021 ; 35 (3) : 240-249. [pub] 20200313

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026028

Grant support
NV15-27109A MZ0 CEP Register

Digital library NLK
Full text - Article

E-resources Online Full text

NLK ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 32203073
DOI 10.1038/s41371-020-0327-3
Knihovny.cz E-resources

Advanced glycation end products (AGEs) are involved in several pathophysiologic processes in vascular diseases, including progressive loss of elasticity of the vessel wall (arterial stiffness). Circulating soluble receptors for AGEs (sRAGE) act as a decoy and counterbalanced the harmful properties of AGEs as the natural protective factor. We compared the role of circulating or skin-deposed AGEs and sRAGE regarding the natural course of arterial stiffening. In a prospective cohort study, we longitudinally followed 536 general population-based subjects (subsample of Czech post-MONICA study). Aortic pulse-wave velocity (PWV) was measured twice (at baseline and after ~8 years of follow-up) using a SphygmoCor device (AtCor Medical Ltd), and the intraindividual change in PWV per year (∆PWV/year) was calculated. Concentrations of sRAGE and carboxymethyl lysine (circulating AGEs) were assessed at the follow-up visit by ELISA, while skin AGEs were measured using the autofluorescence-based device AGE Reader. Using multiple regressions, we found significant association between ∆PWV/year as a dependent variable, and both, sRAGE and skin AGEs as independent ones (each on its own model). However, the closest associations to ∆PWV/year were found for the ratio of these two factors (skin AGEs/sRAGE) [β coeff = 0.0747 (SE 0.0189), p < 0.0001]. In a categorized manner, subjects with skin AGEs/sRAGE ratio ≥ 3.3 showed about twofold higher risk having ΔPWV/year ≥ 0.2 m/s [adjusted odds ratio was 2.09 (95% CI: 1.35-3.22), p = 0.001]. In contrast, neither circulating AGEs nor circulating AGEs/sRAGE showed any significant relation to ΔPWV/year. In conclusion, skin AGEs/sRAGE ratio seems to be a more sensitive biomarker of vascular aging than these single factors themselves or circulation status of AGEs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026028
003      
CZ-PrNML
005      
20211026133249.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41371-020-0327-3 $2 doi
035    __
$a (PubMed)32203073
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Mayer, Otto $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic. mayero@fnplzen.cz $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic. mayero@fnplzen.cz
245    14
$a The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker / $c O. Mayer, J. Gelžinský, J. Seidlerová, M. Mateřánková, Š. Mareš, V. Svobodová, L. Trefil, R. Cífková, J. Filipovský
520    9_
$a Advanced glycation end products (AGEs) are involved in several pathophysiologic processes in vascular diseases, including progressive loss of elasticity of the vessel wall (arterial stiffness). Circulating soluble receptors for AGEs (sRAGE) act as a decoy and counterbalanced the harmful properties of AGEs as the natural protective factor. We compared the role of circulating or skin-deposed AGEs and sRAGE regarding the natural course of arterial stiffening. In a prospective cohort study, we longitudinally followed 536 general population-based subjects (subsample of Czech post-MONICA study). Aortic pulse-wave velocity (PWV) was measured twice (at baseline and after ~8 years of follow-up) using a SphygmoCor device (AtCor Medical Ltd), and the intraindividual change in PWV per year (∆PWV/year) was calculated. Concentrations of sRAGE and carboxymethyl lysine (circulating AGEs) were assessed at the follow-up visit by ELISA, while skin AGEs were measured using the autofluorescence-based device AGE Reader. Using multiple regressions, we found significant association between ∆PWV/year as a dependent variable, and both, sRAGE and skin AGEs as independent ones (each on its own model). However, the closest associations to ∆PWV/year were found for the ratio of these two factors (skin AGEs/sRAGE) [β coeff = 0.0747 (SE 0.0189), p < 0.0001]. In a categorized manner, subjects with skin AGEs/sRAGE ratio ≥ 3.3 showed about twofold higher risk having ΔPWV/year ≥ 0.2 m/s [adjusted odds ratio was 2.09 (95% CI: 1.35-3.22), p = 0.001]. In contrast, neither circulating AGEs nor circulating AGEs/sRAGE showed any significant relation to ΔPWV/year. In conclusion, skin AGEs/sRAGE ratio seems to be a more sensitive biomarker of vascular aging than these single factors themselves or circulation status of AGEs.
650    12
$a stárnutí $7 D000375
650    _2
$a biologické markery $7 D015415
650    12
$a produkty pokročilé glykace $7 D017127
650    _2
$a lidé $7 D006801
650    _2
$a prospektivní studie $7 D011446
650    _2
$a receptor pro konečné produkty pokročilé glykace $7 D000067759
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Gelžinský, Július $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic
700    1_
$a Seidlerová, Jitka $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic
700    1_
$a Mateřánková, Markéta $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic
700    1_
$a Mareš, Štěpán $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic
700    1_
$a Svobodová, Veronika $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic
700    1_
$a Trefil, Ladislav $u Department of Clinical Biochemistry and Hematology, University Hospital, Pilsen, Czech Republic
700    1_
$a Cífková, Renata $u Centre for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Filipovský, Jan $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic
773    0_
$w MED00010020 $t Journal of human hypertension $x 1476-5527 $g Roč. 35, č. 3 (2021), s. 240-249
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32203073 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133255 $b ABA008
999    __
$a ok $b bmc $g 1714903 $s 1146535
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 35 $c 3 $d 240-249 $e 20200313 $i 1476-5527 $m Journal of human hypertension $n J Hum Hypertens $x MED00010020
GRA    __
$a NV15-27109A $p MZ0
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options